4D Molecular Therapeutics 1 article

The company-level identity of 4D Molecular Therapeutics is rooted in Therapeutic Vector Evolution platform, with retinal gene therapy providing the vector or disease-specific context. The company connects intravitreal AAV delivery with pulmonary gene therapy research; genetic cardiomyopathy gene delivery supplies the vector, tissue or expression-control feature that shapes gene delivery. GenoMethods maps vectors, transgenes and individual gene therapies separately; the genetic-medicine profile of 4D Molecular Therapeutics also includes immune evasion in vector design.